Clovis Oncology Inc expected to post a loss of 56 cents a share - Earnings Preview

Clovis Oncology

02/08/2021 15:35

* Clovis Oncology Inc  CLVS.OQ   CLVS.O  is expected to show a
rise in quarterly revenue when it reports results on August 4. 
* The Boulder, Colorado-based company is expected to report   a
3.6% increase in revenue to $41.337 million from $39.89 million
a year ago, according to the mean estimate from 6 analysts,
based on Refinitiv data. 
​* Refinitiv's mean analyst estimate for Clovis Oncology Inc is
for a loss of 56 cents per share. For the same quarter last
year, the company reported a loss of $1.15 per share.
* The current average analyst rating on the shares is "hold" and
the breakdown of recommendations is 1 "strong buy" or "buy," 2
"hold" and 3 "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for Clovis Oncology
Inc is $5.75​, about 16% above​ its last closing price
of $4.83. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Mar. 31 2021  -0.73       -0.72      -0.64     Beat    10.9
 Dec. 31 2020  -0.76       -0.77      -1.02     Missed  -32.5
 Sep. 30 2020  -0.98       -0.99      -0.89     Beat    10.3​
 Jun. 30 2020  -1.03       -1.04      -1.15     Missed  -10.1
 Mar.          -1.24​      -1.28      -1.28     Met     -0.1​
 31​ 2020​                                              
 Dec. 31 2019  -1.67       -1.71      -1.81     Missed  -6​
 Sep. 30 2019  -1.90       -1.89      -1.78     Beat    5.9
 Jun. 30 2019  -1.70       -1.71      -2.27     Missed  -32.4
 This summary was machine generated August 2 at 14:35 GMT.  All
figures in US dollars unless otherwise stated